Corporate Action Relating to bluebird bio's Spin-Off of 2seventy bio
2seventy bio Added to the Cancer Immunotherapy Index
Lenexa, KS -- November 5, 2021 -- On November 4th, 2021, bluebird bio (Nasdaq: BLUE), which previously had both a cancer immunotherapy (CAR-T) related division and a non-cancer related gene therapy division, spun off the cancer immunotherapy division into its own separate publicly traded company, called 2seventy bio (Nasdaq: TSVT). After this spin-off, the legacy company bluebird bio no longer has any cancer focus. As a result, and in accordance with its methodology and focus on cancer immunotherapy, the LCINDX index today has dropped BLUE and replaced its weighting with the cancer immunotherapy focused spinoff TSVT.
Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.
Why immunotherapy: Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.
About the index: The Loncar Cancer Immunotherapy Index is an equal-weighted index of 30 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. This is a sector index similar to Technology sector indices (Internet, Cyber Security, Robotics, etc.). Sector indices allow investors to track interest areas more precisely than broad indices. Additional information can be found at the index’s dedicated website, www.LoncarIndex.com.
Index provider: Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. The company is principally owned by biotech investor and analyst Brad Loncar. Mr. Loncar manages a biotech-focused family portfolio from his Lenexa, Kan. office. He can be followed on Twitter at @bradloncar and his commentary is available at www.loncarblog.com.
Jill Tatios, Gregory FCA for Loncar Investments